pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis.

about

pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis.

Item

http://www.wikidata.org/entity/Q55294849

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

pDCs in lung and skin fibrosis ...... ients with systemic sclerosis.

@en

pDCs in lung and skin fibrosis ...... ients with systemic sclerosis.

@nl

type

Item

label

pDCs in lung and skin fibrosis ...... ients with systemic sclerosis.

@en

pDCs in lung and skin fibrosis ...... ients with systemic sclerosis.

@nl

prefLabel

pDCs in lung and skin fibrosis ...... ients with systemic sclerosis.

@en

pDCs in lung and skin fibrosis ...... ients with systemic sclerosis.

@nl

P1476

pDCs in lung and skin fibrosis ...... ients with systemic sclerosis.

@en

P2093

Anagha A Divekar

http://www.w3.org/2001/XMLSchema#string

Daniel E Furst

http://www.w3.org/2001/XMLSchema#string

Dinesh Khanna

http://www.w3.org/2001/XMLSchema#string

Fereidoun Abtin

http://www.w3.org/2001/XMLSchema#string

Isela Valera

http://www.w3.org/2001/XMLSchema#string

Rajan Saggar

http://www.w3.org/2001/XMLSchema#string

Ram Raj Singh

http://www.w3.org/2001/XMLSchema#string

Suzanne Kafaja

http://www.w3.org/2001/XMLSchema#string

P2860

The immune pathogenesis of scleroderma: context is everything

GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function

Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis

TGF-β activation by bone marrow-derived thrombospondin-1 causes Schistosoma- and hypoxia-induced pulmonary hypertension.

High-resolution computed tomography in the evaluation of fibrosing alveolitis.

Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study.

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease

Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.

Fibrotic disease and the T(H)1/T(H)2 paradigm.

P31

scholarly article

P356

10.1172/JCI.INSIGHT.98380

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29720568

http://www.w3.org/2001/XMLSchema#string

P932

6012518

http://www.w3.org/2001/XMLSchema#string